GLP-1semaglutideindiagenericscardiovascular outcomes

Lancet commentary urges cardiovascular outcome data for India's generic GLP-1s

Authors argue the arrival of low-cost generic GLP-1 receptor agonists creates a chance to generate outcome evidence in South Asian populations.

By Maren Holt · Senior Reporter, GLP-1

Oct 8 20:00 ETSource: The Lancet regional health. Southeast Asia

The wire

01A commentary in The Lancet Regional Health Southeast Asia frames generic GLP-1 receptor agonists entering India as an opportunity to close the cardiovascular evidence gap.
02Clinicians prescribing incretins in South Asia largely extrapolate from trials run in other populations, where baseline cardiometabolic risk differs.
03It is a commentary rather than new data, and whether generic manufacturers or funders will underwrite outcome trials remains unanswered.

From the source

Generic GLP-1 receptor agonists in India: an opportunity to close the cardiovascular evidence gap
The Lancet regional health. Southeast Asia · 2026 Nov · Monjur MR, Alam A et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42898110/